Lantheus Holdings

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and Puerto Rico, third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America, and the EXINI business in Sweden. The company was founded in 1956 and is headquartered in North Billerica, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lantheus reports record revenues in 2022, eyes sustained growth

Lantheus' strong financial performance and market leadership position it well for continued growth.
While facing competition and investment challenges, Lantheus is focused on innovation and market expansion.
The company's strategic acquisitions, pipeline expansion, and guidance for 2023 signal a positive outlook.
Lantheus aims to maintain profitability while investing in key areas for future growth and market leadership.

Lantheus Holdings reports record Q1 results and eyes oncology growth

Lantheus Holdings delivered robust Q1 results driven by key products, with strong revenue and margin performance.
The company's strategic acquisitions and pipeline advancements position them well for future growth in oncology and Alzheimer's diagnostics.
While facing challenges with certain programs and undisclosed cancer types, Lantheus has outlined clear opportunities for market expansion and new treatment avenues.

Lantheus Holdings excels in Q2, eyes European expansion and innovation

Lantheus Holdings delivered robust Q2 2023 results, showcasing strong revenue growth and operational impact, with raised guidance reflecting confidence in sustained performance.
The company's focus on differentiation, market leadership, and strategic partnerships positions it well for growth despite competitive and regulatory challenges.
Opportunities in expanding market reach, diversification through radiotherapeutic candidates, and product innovation present avenues for future growth and market dominance.
Navigating challenges in competition, regulatory changes, and supply chain optimization will be crucial for Lantheus to maintain its market-leading position and drive continued success.

Lantheus Holdings excels in Q3 with strong revenue growth and market leadership

Lantheus Holdings' strong Q3 performance, driven by robust revenue growth and strategic advancements, positions the company well for future success. Despite challenges such as fixed costs and seasonal fluctuations, Lantheus remains focused on leveraging opportunities in the growing radiopharmaceutical market. With a leading market share, innovative pipeline, and solid financial position, Lantheus is poised for continued growth and value creation.

Lantheus Holdings achieves record revenues, eyes growth in radiopharmaceuticals

Lantheus Holdings delivered strong financial performance in 2023 with record revenues and growth.
The company is strategically positioned to capitalize on opportunities in radiopharmaceuticals and oncology.
Challenges include managing potential product transitions and maintaining market leadership.
Overall, Lantheus shows promise for continued growth and innovation in the healthcare sector.

Lantheus Holdings excels in Q1 2024, eyes $1B sales

Lantheus Holdings delivered a strong performance in Q1 2024, driven by robust sales of PYLARIFY and operational excellence, showcasing financial strength and profitability.
The company's focus on innovation, strategic partnerships, and pipeline opportunities positions it well for future growth and market leadership in radioligand therapy.
While facing challenges in a competitive landscape and evolving industry dynamics, Lantheus has opportunities for revenue growth, market expansion, and strategic collaborations to drive long-term success.

Lantheus Holdings excels in Q2 with strong sales and strategic acquisitions

Lantheus Holdings delivered strong financial performance in Q2 2024, driven by PYLARIFY's robust sales and strategic acquisitions strengthening their pipeline.
Despite facing challenges such as regulatory uncertainties and market competition, Lantheus remains well-positioned for growth and market leadership.
With a focus on innovation, market leadership, and strategic acquisitions, Lantheus is poised to capitalize on opportunities in the radiopharmaceutical market and drive sustained growth.

Lantheus Holdings reports robust Q3 performance amidst market opportunities

Lantheus Holdings (LNTH) delivered a strong performance in Q3 2024, driven by key products and revenue growth.
The company faces challenges in navigating market uncertainties and maintaining growth momentum.
Opportunities lie in expanding market presence, capitalizing on reimbursement changes, and advancing Alzheimer's diagnostics.
Overall, Lantheus Holdings shows promise for future growth and innovation in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

Lantheus Holdings (LNTH) is a profitable company with strong products like PYLARIFY and DEFINITY, both showing double-digit growth and dominant market share. Management has demonstrated excellent execution, particularly with PYLARIFY, which is on track to exceed $1 billion in sales by Q4 2024. The company is financially robust, with nearly $1 billion in cash, minimal debt, and strong operating cash flow, positioning it well for acquisitions.

Lantheus Holdings: A Growing Business With Dominant Market Share

Why Lantheus Holdings Stock Won Big on Wednesday

BEDFORD, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announces that its board of directors has authorized a program to repurchase up to $250 million of its common stock during the next twelve months.

Lantheus Announces Share Repurchase Program

BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies London Healthcare Conference at 1:00 p.m. GMT (8 a.m. EST) on Wednesday, November 20.

Lantheus to Present at the Jefferies London Healthcare Conference

BEDFORD, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, notes that the Centers for Medicare & Medicaid Services (CMS) recently posted updated payment rates in Addendum B related to the final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The Company continues to commend CMS for recognizing the value of and ensuring broad patient access to specialized diagnostic radiopharmaceuticals. With PYLARIFY® (piflufolastat F 18) on track to exceed $1 billion in sales in 2024, Lantheus reaffirms its 2025 outlook for PYLARIFY as a blockbuster brand that will continue to be the clear standard and #1 ordered PSMA PET imaging agent in the U.S.

Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025

Lantheus, with a strong pharmaceutical portfolio and double-digit growth, fell 20% post-Q3 2024 due to expected weak Q4 EPS from temporary expenses. Key products Pylarify and Definity enhance diagnostic imaging for prostate cancer and heart conditions, respectively, with significant market potential and government support. Despite a conservative Q4 outlook, Lantheus' forward P/E of 13 and projected 15% annual revenue growth present an attractive buying opportunity.

Lantheus Holdings: Q3 Results Were Good But Market Overreacted

Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob Marshall - CFO Jeff Humphrey - Chief Medical Officer Conference Call Participants Roanna Ruiz - Leerink Partners Anthony Petrone - Mizuho Group Richard Newitter - Truist Securities Matt Taylor - Jefferies Larry Solow - CJS Securities Tara Bancroft - TD Cowen Yuan Zhi - B. Riley Kemp Dolliver - Brookline Capital Markets Justin Walsh - Jones Trading Andy Hsieh - William Blair Ed Ridley-Day - Redburn Atlantic Operator Good morning.

Lantheus Holdings, Inc. (LNTH) Q3 2024 Earnings Call Transcript

BEDFORD, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, applauds the Centers for Medicare & Medicaid Services' (CMS) final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The rule, announced and detailed on the CMS website late Friday, recognizes the value of and ensures broad patient access to specialized diagnostic radiopharmaceuticals by improving the accuracy of payment amounts for these products.

Lantheus Applauds CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care

BEDFORD, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2024, to discuss its financial and operating results for the third quarter of 2024.

Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time

Lantheus stock is approaching a new buy point on the stock market today after finding support at a key level in recent weeks.

Medical Leader Lantheus Headed Toward Buy Point After Support At Key Level

Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses Patients demonstrated statistically significant improvement in time to reduction of health-related quality of life (HRQoL) as measured by Functional Assessment of Cancer Therapy—Prostate (FACT-P) Interim Overall Survival Crossover Adjusted Hazard Ratio was

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors (“Board”), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent.

Lantheus Appoints Julie Eastland as New Board Member

BEDFORD, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 7:45 a.m. ET on Wednesday, September 4.

Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

PYLARIFY is the leading PSMA PET imaging agent, on track to surpass $1 billion in sales by 2024, driving significant revenue growth for Lantheus Holdings, Inc. Lantheus is heavily investing in its oncology and Alzheimer's diagnostics pipeline, positioning itself for substantial long-term growth despite short-term profit impacts. With robust free cash flow, a solid balance sheet, and potential for significant EPS growth, Lantheus Holdings is undervalued and could reach $250 per share by 2028.

Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)

Clearwater Analytics Holdings

Essent Group

H.B. Fuller

Intuitive Surgical

Coca-Cola

Mastercard

MarketAxess Holdings

Sherwin-Williams

Spotify

Union Pacific

XPEL

Now that stock investors are beginning to realize that a recession isn't on the way, the U.S. market will get back to doing what is up to before the August swoon: showing strength beyond the Magnificent Seven.

13 stocks to consider if you're able to brave recession fears

Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob Marshall - CFO Jeff Humphrey - Chief Medical Officer Amanda Morgan - Chief Commercial Officer Conference Call Participants Anthony Petrone - Mizuho Group Roanna Ruiz - Leerink Partners Richard Newitter - Truist Securities Matt Taylor - Jefferies Tara Bancroft - TD Cowen Larry Solow - CJS Securities Yuan Zhi - B. Riley David Turkaly - Citizens JMP Securities LLC Justin Walsh - Jones Trading Andy Hsieh - William Blair Kemp Dolliver - Brookline Capital Markets Richard Newitter - Truist Securities Operator Good morning.

Lantheus Holdings, Inc. (LNTH) Q2 2024 Earnings Call Transcript

Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully diluted earnings per share of $1.80 compared to $1.54 in the second quarter 2023, reflective of inter-quarter investment in business development and R&D.

Lantheus Reports Second Quarter 2024 Financial Results

Atkore International Group

The AZEK Company

Comfort Systems USA

Fabrinet

HealthEquity

Modine Manufacturing

Matador Resources

Onto Innovation

Rush Enterprises

Matador Resources and Onto Innovation are widely held stocks among well-regarded small-cap funds.

10 Stocks That Star Small-Cap Funds Love

BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday,

Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time

Acquisition Expands Pipeline and Strengthens Alzheimer's Diagnostic Capabilities Acquisition Expands Pipeline and Strengthens Alzheimer's Diagnostic Capabilities

Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer's Disease

Lantheus, known for its radiopharmaceutical Pylarify, experienced a significant boost following positive CMS payment updates. Pylarify's increased revenue contributed significantly to Q1 earnings, reflecting a robust market demand for this leading prostate cancer imaging agent. Lantheus maintains financial health with ample cash reserves and manageable long-term debt, underscoring strong operational capabilities.

Lantheus' Strategic Advantage Amplified By New CMS Payment Refinements (Rating Upgrade)

BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced that it welcomes the Centers for Medicare & Medicaid Services' (CMS') Proposed Medicare Hospital Outpatient Prospective Payment System (OPPS) Rule for calendar year 2025 for improved payment for specialized diagnostic radiopharmaceuticals to support patient access for Medicare beneficiaries.

Lantheus Welcomes CMS' Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access

Medicare will likely soon change how it pays for diagnostic radiopharmaceuticals. Lantheus should be a big winner from this reimbursement change.

Why Lantheus Holdings Stock Is Skyrocketing Today

Lantheus stock rocketed to a 13-month high Wednesday after a Medicare proposal suggested hiking the reimbursement rate for some diagnostics.

Lantheus Stock Gets A Radioactive Surge On Medicare Proposal

BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Jamie Spaeth to its Executive Team as Chief People Officer.

News for Lantheus Holdings Stock (LNTH)